Navigation Links
New Research Shows That Combining Aerobic Exercise With High-Force Eccentric Resistance Training Improves Glucose Control in Diabetes Patients
Date:10/31/2008

or People With Diabetes" is available at: http://www.ptjournal.org/misc/podcasts.dtl. The podcast highlights PTJ's Diabetes Special Issue: "People With Diabetes: A Population Desperate for Movement." (November 2008). Marcus and other experts discuss new information about the roles of fat in people with diabetes, especially fat in muscle, and about how this fat appears to impair muscle function. Running time: 24:29 (11,487 KB).

Paul LaStayo, PT, PhD, the study's senior author, notes that the eccentric resistance exercise program was specifically designed to increase strength and muscle size, using a recumbent stepper that produced a lengthening contraction, such as when lowering the dumbbell in a bicep curl.

After 3 months, Marcus and LaStayo found that both groups showed improved glucose control and physical performance in a 6-minute walk, as well as a decrease in fat composition within the leg muscles. "This study is particularly interesting because the patients who did both aerobic and resistance exercise had additional improvements, most notably a decreased overall BMI and a gain in leg muscle," Marcus said.

"Although aerobic exercise is still key in treating diabetes, it should not be used in isolation," Marcus observes. "As people age, they lose muscle mass and, subsequently, mobility, resulting in a greater risk of falls. Adding resistance training to the diabetes treatment regimen leads to improved thigh lean tissue which, in turn, may be an important way for patients to increase resting metabolic rate, protein reserve, exercise tolerance, and functional mobility, she notes.

This study is part of PTJ's special issue (http://www.ptjournal.org/current.dtl) on diabetes, which illustrates that physical therapy interventions can have a dramatic and positive effect in fighting the complications associate
'/>"/>

SOURCE American Physical Therapy Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Opt out system could solve donor organ shortage, says researcher
2. Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows
3. Halpin Foundation and the ASN announce recipient of Halpin Foundation-ASN research grant
4. International Society for Stem Cell Research Highlights New YouTube Channel Providing Accurate Scientific Perspectives on Stem Cell Research
5. Weill Cornell Medical College receives 2 $100,000 grants for innovative global health research
6. HealthMetrix Research Selects 2009 Medicare Advantage Plans for Best Overall Benefit Value
7. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis
8. Cancer requires support from immune system to develop, UT Southwestern researchers report
9. Research Reveals Why Tamoxifen Doesnt Always Work
10. National grants further WA Medical Research
11. Susan G. Komen Breast Cancer Foundation awards grant for imaging-agent research
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:dLife Launches the World's Largest and Most Comprehensive Online Food and Diabetic Recipe Search Tool 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 1Express Scripts Launches Equity Offering to Finance Acquisition 47588 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 1Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 2Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 4Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 5Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 1Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 3
Other Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5